急性白血病患者血浆TF、TFPI及IL-1β；动态变化分析

本研究旨在探讨血浆组织因子（TF）、组织因子途径抑制物（TFPI）和白介素-1β（IL-1β）在急性白血病（AL）患者病情进展、疗效观察及预后判断中的意义。用酶联免疫吸附方法（ELISA）测定20例健康体检者及24例AL患者化疗前血浆TF、TFPI、和IL-1β的含量，并测定初治AL患者在进行化疗第72小时、缓解3个阶段血浆TF、TFPI、和IL-1β的含量。结果表明：24例初治AL患者首次诱导化疗前血浆TF、TFPI、和IL-1β含量较正常对照组高，差异有显著性（P〈0．01）；化疗第72小时血浆TF和IL-1β含量明显高于首次诱导化疗前，有显著性差异（P〈0．05），但血浆TFPI与化疗前相比明显下降，也有显著性差异（P〈0．01）；24例初治AL患者16例缓解，缓解组血浆TF、TFPI和IL-1β含量降至正常，与正常对照组比无显著性差异（P〉0．05）。结论：TF、TFPI和IL-1β是判断急性白血病患者病情进展、疗效观察及预后的重要指标。

Analysis of the Dynamic Change of TF, TFPI and IL-1β in Plasma of Patients with Acute Leukemia

This study was purposed to explore the significance of tissue factor (TF), tissue factor pathway inhibitor (IFPI) and interleukin-1beta (IL-1beta) in the evaluation of development, curative effect and prognosis of AL patients. ELISA was used to detect the levels of TF, TFPI and IL-1beta in plasma of 20 healthy individuals and 24 newly diagnosed AL patients. All the three indications of patients were measured in different stages including pre-chemotherapy phase, at 72 hours after chemotherapy, complete remission phase. The results showed that as compared with normal control, levels of TF, TFPI and IL-1beta in plasma of AL patients during pre-chemotherapy phase were higher (p < 0.01); as compared with pre-chemotherapy phase, levels of TF, IL-1beta were elevated at 72 hours after -chemotherapy (p < 0.05). However, the levels of TFPI was much lower than that of 72 hours after chemotherapy (p < 0.01). 16 out of 24 patients got complete remission, there was no difference of TF, TFPI and IL-1beta between complete remission group and normal control group. It is concluded that the levels of TF, TFPI and IL-1beta in plasma can be used as the indicators for understanding clinical features, evaluating disease status and predicting prognosis in acute leukemia patients.